Work

Efficacy and Safety of Tavapadon, an Orally Administered, Once-daily, Selective D1/D5 Partial Dopamine Agonist, Adjunctive to Levodopa for Treatment of Parkinson’s Disease with Motor Fluctuations (S37.003)

Year: 2025

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000208468

Authors: Hubert Fernandez, Stuart Isaacson, Robert Hauser, Pinky Agarwal, William Ondo, Ariane Park, Lawrence Elmer, Daniel Kremens, Matthew Leoni, Sridhar Duvvuri, Cari Combs, Erica Koenig, Ih Chang, Gina Pastino, Stacey Tringali, Nicole Golonski, Raymond Sanchez

Institutions: Cleveland Clinic, University of South Florida, Evergreen Health Medical Center, Houston Methodist, The Ohio State University Wexner Medical Center, University of Toledo, Thomas Jefferson University, Cerevel Therapeutics (United States)

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409225955

FWCI: 1.691

Cites:

Cited by: 3

Related to: 10